BridgeBio Pharma
BBIO
195 hedge funds and large institutions have $2.37B invested in BridgeBio Pharma in 2021 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 72 increasing their positions, 65 reducing their positions, and 51 closing their positions.
67% more call options, than puts
Call options by funds: $122M | Put options by funds: $72.8M
11% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 65
3.03% more ownership
Funds ownership: 93.48% → 96.51% (+3%)
7% less funds holding
Funds holding: 210 → 195 (-15)
27% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 51
64% less capital invested
Capital invested by funds: $6.56B → $2.37B (-$4.19B)
67% less funds holding in top 10
Funds holding in top 10: 15 → 5 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$53.3M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$50.7M |
| 3 |
D.E. Shaw & Co
New York
|
+$47.4M |
| 4 |
Citigroup
New York
|
+$31.1M |
| 5 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
+$29.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$111M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$37.3M |
| 3 |
BlackRock
New York
|
-$36.6M |
| 4 |
PA
Perceptive Advisors
New York
|
-$26.6M |
| 5 |
BAMCO Inc
New York
|
-$22.8M |
BBIO Hedge Fund Activity: Q4 2021 in Review
195 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2021, worth a combined $2.37B — down 64% from $6.56B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of BBIO and 37 opened new positions — a net loss of 14 holders — while 65 trimmed existing stakes and 72 added.
The largest buyer was Millennium Management, adding an estimated $53.3M. The largest seller was Janus Henderson Group, cutting an estimated $111M.
- 195 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2021, down from 210 in Q3 2021.
- Funds reported $2.37B of BridgeBio Pharma stock for Q4 2021, down 64% quarter-over-quarter.
- 37 funds opened new BridgeBio Pharma positions in Q4 2021 and 51 closed out, a net change of -14 holders.
- The largest BridgeBio Pharma buyer in Q4 2021 was Millennium Management, an estimated $53.3M added.
- The largest BridgeBio Pharma seller in Q4 2021 was Janus Henderson Group, an estimated $111M sold.
Based on aggregated 13F filings for Q4 2021.